REGENXBIO to Participate in Upcoming Investor Conferences

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) has announced its participation in two key investor conferences:

• Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 2:55 p.m. ET in New York.
• UBS Biotech South Beach Conference on September 29, 2022, in Miami.

A live webcast of the Morgan Stanley conference will be available on REGENXBIO's website with a 30-day archived replay. The company is committed to advancing gene therapy through its proprietary NAV Technology Platform and aims to progress five AAV Therapeutics by 2025.

News Market Reaction – RGNX

-9.12%

-9.12% Session move

In the trading session that priced this news, RGNX declined 9.12%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., Sept. 6, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences:

Morgan Stanley 20th Annual Global Healthcare Conference
Date: Wednesday, September 14, 2022
Fireside chat: 2:55 p.m. ET
Location: Sheraton Hotel, New York, NY

UBS Biotech South Beach Conference 2022
Date: September 29, 2022
Location: Mondrian South Beach, Miami, FL

A live webcast of the Morgan Stanley 20th Annual Global Healthcare Conference fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301618022.html

SOURCE REGENXBIO Inc.

FAQ

What are the upcoming investor conferences for REGENXBIO (RGNX)?

REGENXBIO will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, and the UBS Biotech South Beach Conference on September 29, 2022.

When is REGENXBIO's fireside chat at the Morgan Stanley conference?

The fireside chat at the Morgan Stanley conference is scheduled for September 14, 2022, at 2:55 p.m. ET.

Will there be a live webcast for the Morgan Stanley conference?

Yes, a live webcast of the Morgan Stanley conference will be accessible on REGENXBIO's website.

What is REGENXBIO's goal for 2025?

REGENXBIO aims to advance five AAV Therapeutics into pivotal-stage or commercial products by 2025.

Where is the UBS Biotech South Beach Conference being held?

The UBS Biotech South Beach Conference will take place at the Mondrian South Beach in Miami, FL.